Table 1.

Characteristics of 271 patients with ductal carcinoma in situ (DCIS), with and without invasive breast cancer

			DCIS
	All patients		DCIS only		DCIS with invasive cancer
	N	(%)	N	(%)	N	(%)
Total	271	(100.0)	120	(100.0)	151	(100.0)
Age at diagnosis, years
<40	24	(8.9)	4	(3.3)	20	(13.2)
40–49	90	(33.2)	43	(35.8)	47	(31.1)
50–64	90	(33.2)	36	(30.0)	54	(35.8)
≥65	67	(24.7)	37	(30.8)	30	(19.9)
Year of breast cancer diagnosis
2000–2003	226	(83.4)	97	(80.8)	129	(85.4)
2004–2007	43	(15.9)	22	(18.3)	21	(13.9)
2008–2011	2	(0.7)	1	(0.8)	1	(0.7)
Race
Missing	5	(1.8)	2	(1.7)	3	(2.0)
Hispanic	10	(3.7)	4	(3.3)	6	(4.0)
Non-Hispanic (NH) white	199	(73.4)	81	(67.5)	118	(78.1)
NH black	4	(1.5)	3	(2.5)	1	(0.7)
NH Asian/Pacific Islander	53	(19.6)	30	(25.0)	23	(15.2)
Socioeconomic status
Missing	30	(11.1)	19	(15.8)	11	(7.3)
1 (Lowest)	4	(1.5)	2	(1.7)	2	(1.3)
2	15	(5.5)	8	(6.7)	7	(4.6)
3	23	(8.5)	9	(7.5)	14	(9.3)
4	40	(14.8)	10	(8.3)	30	(19.9)
5 (Highest)	159	(58.7)	72	(60.0)	87	(57.6)
Hormone receptors
Missing	12	(4.4)	0	0	12	(7.9)
Either ER or PR positive	137	(50.6)	65	(54.2)	72	(47.7)
Both ER and PR negative	122	(45.0)	55	(45.8)	67	(44.4)
Stage
Missing	4	(1.5)	0	0	4	(2.6)
Stage 0	120	(44.3)	120	(100.0)	0	0
Stage I	69	(25.5)	0	0	69	(45.7)
Stage II	69	(25.5)	0	0	69	(45.7)
Stage III	8	(3.0)	0	0	8	(5.3)
Stage IV	1	(0.4)	0	0	1	(0.7)
Grade
Missing	2	(0.7)	1	(0.8)	1	(0.7)
1	56	(20.7)	27	(22.5)	29	(19.2)
2	130	(48.0)	57	(47.5)	73	(48.3)
3	83	(30.6)	35	(29.2)	48	(31.8)
HER2 gain
No gain	182	(67.2)	83	(69.2)	99	(65.6)
Gain	89	(32.8)	37	(30.8)	52	(34.4)

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2